“ngm-biopharmaceuticals” Archives

in
Entry Author Date Location
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More 03/13/20 National
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More 02/28/20 National
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data 02/24/20 San Francisco
Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More 04/05/19 National
NGM Bio’s IPO Raises $107M as NASH Drug Continues Clinical Testing 04/03/19 San Francisco
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More 03/29/19 National
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More 03/22/19 National
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
Pursuing Larger Rivals, NGM Bio Tries To Make Mark On Fatty Livers 04/22/17 San Francisco
NGM Biopharmaceuticals Secures $105,999,996 Series E Financing Round 03/26/15 San Francisco
West Coast Biotech Roundup: Flexus, NGM, Illumina, Bob Klein & More 02/26/15 San Francisco
NGM Biopharmaceuticals Lands $20,710,000 Series D Funding 02/24/15 San Francisco
Well-Funded NGM Bio Nabs $200M To Boost Merck’s Metabolic Pipeline 02/23/15 San Francisco
NGM, Partners Seek Next Diabetes Drug Targets Among GI Tract Hormones 06/25/13 San Francisco
NGM Biopharmaceuticals Secures $13,485,015 Series C Funding Round 05/03/13 San Francisco
NGM Biopharmaceuticals Obtains $51,000,000 Series B Funding Round 03/15/10 San Francisco
NGM Biopharmaceuticals Garners $9,600,000 New Funding 12/31/09 San Francisco
NGM Biopharmaceuticals Obtains $8,500,000 New Funding 03/31/09 San Francisco
Page 1 of 1